(IN BRIEF) AstraZeneca and Daiichi Sankyo have secured European Union approval for Enhertu as a tumour-agnostic monotherapy for adults with previously treated HER2-positive IHC 3+ unresectable or metastatic solid tumours who have no satisfactory treatment alternatives. The decision is the … Read the full press release →
Posted in Business, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, AstraZeneca, Benedikt Westphalen, biomarker testing, breast cancer, cancer treatment, CHMP, colorectal cancer, Daiichi Sankyo, Dave Fredrickson, DESTINY-Breast01, DESTINY-CRC02, DESTINY-Lung01, DESTINY-PanTumor02, EMA, Enhertu, Enhertu Approval Brings HER2-Directed Antibody Drug Conjugate Therapy to Broader Solid Tumour Population, European Commission, European Medicines Agency, gastric cancer, HER2 testing, HER2-positive solid tumours, Ken Keller, metastatic cancer, New EU Enhertu Indication Expands Targeted Treatment Options Beyond Individual Tumour Types, non-small cell lung cancer, objective response rate, oncology, Phase II Evidence Supports EU Tumour-Agnostic Approval of Enhertu for HER2-Positive Cancers, precision oncology, targeted therapy, trastuzumab deruxtecan, tumour-agnostic therapy, unresectable cancer
(IN BRIEF) AstraZeneca and Daiichi Sankyo have received European Union (EU) approval for their drug Enhertu as a monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in adult patients with activating HER2 mutations who require systemic therapy … Read the full press release →
Posted in Business, Environment, European Union, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Daiichi Sankyo, Dave Fredrickson, Enhertu, EU approval, HER2-Mutant, Ken Keller, lung cancer, Martin Reck, monotherapy, NSCLC, partnership, sustainability
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Digi Communications NV announces availability of Digi Spain’s H1 2026 financial results presentation
Load more...
